Navigation Links
The Bottom Line on Colon Cancer: Get Screened
Date:3/4/2011

SEATTLE, March 4, 2011 /PRNewswire/ -- Despite the fact that colon cancer screening saves lives, the majority of U.S. adults age 50 and over who are eligible for such screening fail to take advantage of it. Consider the numbers: In 2000, only 16.3 million of 80 million eligible adults (about 20 percent) received colon cancer screening such as the fecal occult blood test (the most popular choice), sigmoidoscopy or colonoscopy.

While each form of colon cancer screening has its advantages and disadvantages, people are often squeamish about anything having do with the subject.

"The important thing is to do at least one of the tests once you reach age 50," said William Grady, M.D., a colorectal cancer specialist at Seattle Cancer Care Alliance and member of the Clinical Research Division at Fred Hutchinson Cancer Research Center.

While diet and exercise may play a role in preventing colon cancer, the most important way to prevent death from the disease is through early detection, Grady said. "This means regular colorectal cancer screening tests beginning at age 50 -- earlier if you are at higher risk. If all colon-cancer cases were detected at their earliest stages, five-year overall survival rates would jump from 65 percent to 90 percent."

In  honor of National Colorectal Cancer Awareness Month, this month the Hutchinson Center is reprising its "End Colon Cancer Now" awareness campaign that features a website containing information about screening and a quick test to assess your risk of colon cancer.

Grady and other screening advocates are adamant about colon cancer screening because even though it is preventable, it remains the second-leading cause of cancer death in the U.S. It is also one of the most commonly diagnosed cancers in the U.S., occurring more than 90 percent of the time in people age 50 and older.

Following is a summary of the currently available colon cancer screening tests:

* Fecal Occult Blood Test (FOBT): This is a safe and simple test and is most effective if done annually. It involves a take-home kit available from the doctor's office that tests for the presence of blood in the stool. The downside to FOBT is it is not specific to detecting cancer, just blood, which can be a symptom of colon cancer. FOBT has a high false-positive rate. If blood is detected in the stool, the patient will be referred for a sigmoidoscopy or colonoscopy.

* Flexible sigmoidoscopy: Similar to a colonoscopy in that a flexible tube is inserted into the colon via the rectum. A scope looks for growths called polyps on the membrane wall; polyps can be precursors to cancer. Although this test only needs to be done once every five years, it does not examine the entire colon and does not have the ability to remove any polyps that are found.

* Colonoscopy: The current "gold standard" of screening tools, according to Grady, because it only needs to be done once every 10 years in people of normal risk. The scope examines the entire colon and contains a tool to painlessly remove polyps instantly. The downside is mostly the perception that preparing for the test and the exam itself are uncomfortable. However, the process of emptying the colon in advance of the test - taking a special laxative - can be done at home in two parts prior to coming to the clinic for the exam. Patients are usually sedated for the 15-30-minute colonoscopy itself and usually feel nothing.

* Newer, non-invasive high-tech tests are available, such as virtual colonoscopy and CT colonography, however, these radiological exams still require colon-cleansing preparations and cannot remove any polyps that are found.

* In the future, simple blood tests that can detect molecular markers for colon cancer will be available. Grady is a leading researcher in this area. Developing an effective blood test is important because it will greatly increase the rate of screening.

Persons with hereditary risk factors for colon cancer, such as first-degree relatives who had colon cancer, need to be screened earlier and perhaps more often, said Grady, who recommends that such patients talk to their doctor for screening recommendations.

Washington is among 27 states that mandate health insurance coverage of colon cancer screening, which helps to eliminate the financial obstacle to testing.

About Seattle Cancer Care Alliance - 10 Years, Thousands of Lives Saved

Every day, the goal of Seattle Cancer Care Alliance is to turn cancer patients into cancer survivors. SCCA unites the adult and pediatric cancer-care programs of Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's. Together they comprise the only National Cancer Institute-designated comprehensive cancer center in six states, from Washington to the Dakotas. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside. Patients receive the latest research-based cancer therapies as well as cutting-edge treatments. SCCA has three clinical-care sites: an outpatient clinic on the Hutchinson Center campus, a pediatric-inpatient unit at Children's and an adult-inpatient unit at UW Medical Center. SCCA celebrates its 10th anniversary in 2011. For more information visit www.seattlecca.org

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.Dean Forbes206-667-2896dforbes@fhcrc.org
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Better batteries from the bottom up
2. Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
3. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
4. North America automobile sector bottom of world sustainability league
5. Bottoms up: Better organic semiconductors for printable electronics
6. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Living longer: Colon cancer patients gain time with radiofrequency ablation treatment
9. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):